|
131 |
Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors
Enthalten in Nature medicine Bd. 31, 25.3.2025, Nr. 5, date:5.2025: 1567-1577
|
|
|
|
132 |
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
Enthalten in Nature Bd. 566, 7.2.2019, Nr. 7745, date:2.2019: E13
|
|
|
|
133 |
Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial
Enthalten in BMC cancer Bd. 10, 6.10.2010, Nr. 1, date:12.2010: 1-8
|
|
|
|
134 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
Enthalten in BMC cancer Bd. 10, 6.9.2010, Nr. 1, date:12.2010: 1-9
|
|
|
|
135 |
Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study
Enthalten in Acta neuropathologica Bd. 143, 31.3.2022, Nr. 5, date:5.2022: 609-612
|
|
|
|
136 |
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
Enthalten in Acta Neuropathologica Communications Bd. 6, 2.3.2018, Nr. 1, date:12.2018: 1-9
|
|
|
|
137 |
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Enthalten in Acta neuropathologica Bd. 142, 5.8.2021, Nr. 5, date:11.2021: 827-839
|
|
|
|
138 |
Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk–benefit analysis
Enthalten in Journal of neuro-oncology Bd. 167, 9.2.2024, Nr. 2, date:4.2024: 245-255
|
|
|
|
139 |
Retraction Note: Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients
Enthalten in Quality of life research Bd. 33, 31.5.2024, Nr. 8, date:8.2024: 2297
|
|
|
|
140 |
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1
Enthalten in Acta neuropathologica Bd. 138, 27.6.2019, Nr. 3, date:9.2019: 497-504
|
|
Administration
